Humoral Immune System Plays a Major Role in Immunity to Influenza
The influenza vaccine considered in this study is the trivalent inactivated vaccine (TIV) administered by intramuscular injection. The effective components of TIV are hemagglutinin (HA) and neuraminidase (NA) that noticeably induce the humoral immunity but activate the cellular immunity less vigorously (Doherty and Kelso 2008) . The other, cold-adaptive trivalent live attenuated influenza vaccine (LAIV) is also believed to induce the cellular immunity to a low level (Doherty and Kelso 2008) . The humoral immunity greatly relies on the antigenic distance between the hemagglutinin of the vaccine and that of the dominant circulating strain. On the other hand, the cellular immune system focuses on the highly conserved internal proteins, which are the Matrix protein 1 (M1) and the nucleoprotein (NP) (Lee et al. 2008) . In contrast to the antibodies, CD8+ and CD4+ T cells show notable cross immunity to a wide variety of strains (Lee et al. 2008) . Like the cellular immune system, the antigen-unspecific innate immune system generates a homogeneous immune reaction against different influenza strains (Janeway et al. 2005) .
For all these reasons ferret antisera, in which antibodies are the major immune component, is used in the hemagglutination inhibition (HI) assay as the conventional way to measure the antigenic distance between the vaccine strain and the dominant circulating strain. Therefore, we consider the antibody rather than the cellular or innate immune system to be the dominant element in our quantification of antigenic distance between two influenza strains and the key factor for influenza vaccine effectiveness.
Evaluation of Vaccine Effectiveness
By definition, vaccine efficacy is measured by controlled trials with initially susceptible subjects, while vaccine effectiveness is measured by epidemiological observance of susceptible population without giving placebo (Kelly et al. 2009 ). Vaccine efficacy is relatively more idealized than vaccine effectiveness, because vaccine effectiveness depends on vaccine efficacy and other environmental factors (Torvaldsen and McIntyre 2002) . Although the terms vaccine efficacy and vaccine effectiveness are interchangeable to some extent (Torvaldsen and McIntyre 2002) , we use the term vaccine effectiveness because factors other than vaccine strain and dominant circulating strain are involved in the studies used in our metaanalysis. The data source for vaccine effectiveness calculation used ILI as the primary endpoint, and studies we use contained controlled unvaccinated groups.
The data from four studies require additional clarification. The paper by Edwards et al. (Edwards et al. 1994 ) did not provide the retrospectively reported influenza-like illness data prior to the 1987-88 season, so we use the number of ill subjects presenting for throat culture to calculate the morbidity rate u and v. Note that in this study, subjects with influenza-like disease were required to show up for a throat culture, and when characterized by vaccination status the numbers of such patients is thus a reasonable estimation of the illness rate u and v. Moreover, in other seasons when both retrospective data and number of presenting ill subjects were available, the vaccine effectiveness calculated from retrospective data and numbers of presenting ill subjects are similar to each other, especially for subtype H1N1 (Edwards et al. 1994) . In Grotto et al.'s study (Grotto et al. 1998 ) using influenza strains from Israel in the 1995-96 season, the numbers of sampled H1N1 and H3N2 strains in Israel was 7 and 35, respectively. The samples were collected from six clinics in December that was in the middle of the influenza season. However, the number of both subjects and viruses sampled are limited. At the global level with more available data, it was observed that H1N1 and H3N2 were co-circulating with comparable frequencies, and H1N1 virus was found in North America and part of Eurasia including Israel (Centers for Disease Control and Prevention (CDC) 1996). The proportion of H1N1 in samples during the 1995-96 season in USA ranks #5 in H1N1 proportion since 1977 (Ferguson et al. 2003 ). In the same season, H3N2 vaccine strain and dominant circulating strain were a perfect match, so the decrease in the overall vaccine effectiveness is expected to be due to the mismatch in the H1N1 component. Therefore we treat H1N1 here as a co-circulating strain and take into account the vaccine effectiveness reported in this article (Grotto et al. 1998 ). Keitel et al. (Keitel et al. 1997) reported that the dominant circulating strain in the 1983-84 season was A/Chile/1/83 rather than A/Victoria/7/83 in this table and in other cited studies. The illness rate u and v are small, and so the standard error of vaccine effectiveness is 64.8%, which is unacceptable. Thus the use of Keitel et al.'s data for 1983-84 season is not appropriate to the vaccine effectiveness assessment. The reference by Couch et al. (Couch et al. 1996) did not provide original data n u , N u , n v , and N v for the calculation of vaccine effectiveness. Error bars of vaccine effectiveness in these seasons were calculated with other data sources.
Robustness of the p epitope Model
Influenza vaccine effectiveness may depend not only on the antigenic distance between the vaccine strain and the dominant circulating strain quantified by p epitope , but also on the percentage of people vaccinated, the time of vaccination in the influenza season, influenza virus transmissibility and reproduction rate, and individual's immune history. Thus, development of the public health system and a greater fraction of the population being vaccinated may result in a trend of both H1N1 and H3N2 vaccine effectiveness. The statistics of vaccine effectiveness could be biased by these factors. Nevertheless, greater than 50% of the H1N1 and H3N2 vaccine effectiveness are explained by p epitope , since R 2 > 1/2. To show that the model of vaccine effectiveness can be well reduced to a linear form between p epitope and vaccine effectiveness, we calculated the residuals of linear regression of vaccine effectiveness on p epitope , and performed another linear regression of these residuals versus year. The trend line of the residuals has a slope of −0.0002/year and the null Figure S1 : The linear regression with R 2 = 0.0003 of the residuals of H1N1 vaccine effectiveness versus year. Data from Table 1 and Figure 2 in the main text. The slope of the trend line is −0.0002/year. ANOVA test: H 0 : slope = 0, F = 0.0021, and p = 0.96. The null hypothesis that these residuals are independent of time cannot be rejected.
Residuals of H1N1 Vaccine Effectivenesses
hypothesis that the slope equals zero is not rejected (p = 0.96), as shown in Figure S1 . The residuals of H3N2 vaccine effectiveness (Gupta et al. 2006) were also correlated with the year and the slope −0.0013/year is not significantly different with zero (p = 0.58), as shown in Figure S2 . Therefore the contribution of other simple time-dependent factors other than p epitope to H1N1 and H3N2 vaccine effectiveness in humans is negligible. Our analysis suggests that the vaccine effectiveness data in this paper are negligibly affected by these potential biases.
Despite the limited number of available data points in this study, the correlation line between the p epitope and the vaccine effectiveness has statistical meaning. In Figure 2 in the main text, the trend line is vaccine effectiveness = −1.19 p epitope + 0.53, the greatest determinant of which is the data point 1986-87 (b). If this data point is removed, the trend line becomes vaccine effectiveness = −1.63 p epitope + 0.54, which is not fundamentally distinct with the original trend line. In the data point 1986-87 (b), the difference of the vaccine effectiveness predicted by these two models is 0.13, which is roughly one standard error. In reality, most p epitope values are less than 0.1, and so most of the differences between these two predicted vaccine effectiveness values are less than 0.034, which is within the noise levels of the epidemiological measurements. Figure S2 : The linear regression with R 2 = 0.018 of the residuals of H3N2 vaccine effectiveness versus year. Data from (Gupta et al. 2006) . The slope of the trend line is −0.0013/year. ANOVA test: H 0 : slope = 0, F = 0.32, and p = 0.58. The null hypothesis that these residuals are independent of time cannot be rejected.
Residuals of H3N2 Vaccine Effectivenesses
The basis for calculating p epitope is a set of well defined epitopes. An early definition of the five epitopes in H1 hemagglutinin (Caton et al. 1982 ) did not identify numerous amino acid positions in which mutations were frequently selected in history. These positions are presumably under strong antigenic pressure to be selected for escape mutation. The more recent definition of H1 epitopes incorporates these additional amino acid positions as well as amino acids from the epitopes of H3 hemagglutinin (Deem and Pan 2009) . Likely additional experiments on the H1 epitopes will allow further refinement of the calculation of p epitope . Only nine epidemiological data points are available since the reemergence of H1N1 virus in humans in 1977. The p epitope model parameters may be further improved as epidemiological data are accumulated.
The antigenic properties are determined by a small number of amino acid substitutions, because the positions and the amino acids introduced by mutation have distinct effects on the change of antigenic distance between vaccine strain and dominant circulating strain. For example, mutations yielding charged amino acids in the dominant epitope are favorable for the virus, and may be the key amino acid substitution for the antigenic properties (K. Pan et al., submitted). An improved sequence-based model might assign different amino acid substitutions with weights determined by the decrease of binding constant between HA and antibody using free energy calculation (K. Pan and M. W. Deem, submitted) . With the current knowledge, the less precise but safe p epitope model assigns the amino acid substitutions in the dominant epitope with weight one, and assigns other amino acid substitutions with weight zero. The p epitope model can nevertheless correlate with the vaccine effectiveness better than the antisera data. That is, for both H1N1 and H3N2, the p epitope method is superior to other methods in current use.
Comparison of the p epitope Model and the HI Assay for H3N2 Virus
In some cases p epitope model detects antigenic variants better than the HI assay. (Harper et al. 2004) ), the vaccine effectiveness was only moderate (Gupta et al. 2006) . Interestingly, the p epitope between A/Fujian/411/2002 and A/Wyoming/3/2003 was also moderate (p epitope = 0.095), predicting the moderate vaccine effectiveness. In fact, the p epitope method can also detect antigenic variants more rapidly as they emerge (He and Deem 2010) .
